What are the recommendations for patients suffering from
severe conjunctivitis and keratoconjunctivitis during the COVID-19
pandemic?
Patients should continue baseline treatment as established by their
physician and current guidelines. According to a panel of experts,
low-dose corticosteroids or antiallergic eye drops continue to be the
first line of treatment for allergic conjunctivitis during the current
pandemic. Although there is no evidence on the possible effect of
SARS-CoV-2 on patients using ocular immunomodulating drugs, in patients
with vernal keratoconjunctivitis and allergic keratoconjunctivitis the
use of local immunomodulatory treatment is considered safe in
non-infected patients and should be monitored closely in those with
active infection. The use of systemic immunosuppressants for severe
COVID-19 cases should be considered on an individual
basis117.